Oric Pharmaceuticals, Inc. - 8-K Filing
On June 18, 2026, Oric Pharmaceuticals held its annual meeting where shareholders approved an amended and restated 2020 Equity Incentive Plan. The plan amendments included reducing the annual share increase from 5% to 4%, removing a fixed annual limit of 2,656,500 shares, capping incentive stock options at 10 million shares, and eliminating certain award modification provisions. Shareholders also elected two Class III directors (Jacob M. Chacko, M.D., and Mardi C. Dier), ratified KPMG as auditors with 99.97% approval, approved executive compensation with 96.85% support, and voted to hold annua... (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 5.07 Submission of Matters to a Vote of Security Holders, 9.01 Financial Statements and Exhibits)
Tickers: $ORIC